Fri, Sep 19, 2014, 7:43 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Halozyme Therapeutics, Inc. Message Board

  • dickunger2 dickunger2 Dec 21, 2013 10:39 AM Flag


    I wrote the EMA and this is the answer I got back:Dear Mr
    Thank you for your query of 19 November 2013 regarding an on-going procedure for Mabthera.
    A revised version of the Risk Management Plan (RMP) for this product will be discussed at the Pharmacovigilance Risk Assessment Committee (PRAC) meeting in January; the minutes of this meeting will be published on the European Medicines Agency’s (EMA) website around mid-February:
    Please note that the EMA is not able to comment further on the status of on-going evaluations until such evaluation is concluded.
    We hope you find this information helpful.
    Kind regards,
    Rosa Gonzalez-Quevedo
    Stakeholders and Communication
    European Medicines Agency\
    7 Westferry Circus | Canary Wharf | London E14 4HB | United Kingdom Less

    SortNewest  |  Oldest  |  Most Replied Expand all replies
9.80-0.08(-0.81%)Sep 19 4:15 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.